627 related articles for article (PubMed ID: 18549431)
1. Roles of the urologist and nurse from the perspective of patients with prostate cancer receiving luteinizing hormone-releasing hormone analogue therapy.
Lebret T; Bouregba A
BJU Int; 2008 Nov; 102(10):1419-24. PubMed ID: 18549431
[TBL] [Abstract][Full Text] [Related]
2. Assessing the attitudes to prostate cancer treatment among European male patients.
Schulman C
BJU Int; 2007 Jul; 100 Suppl 1():6-11. PubMed ID: 17593202
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life among patients with metastatic prostate cancer.
Albertsen PC; Aaronson NK; Muller MJ; Keller SD; Ware JE
Urology; 1997 Feb; 49(2):207-16; discussion 216-7. PubMed ID: 9037282
[TBL] [Abstract][Full Text] [Related]
4. [The role of a 6-month depot form of hormone therapy in the treatment of advanced hormone-dependent prostate cancer: Results from the 'ELIRE' observational study].
Ouzaid I; Rouprêt M
Prog Urol; 2011 Nov; 21(12):866-74. PubMed ID: 22035913
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of an evidence-based education package for men with prostate cancer on hormonal manipulation therapy.
Templeton H; Coates V
Patient Educ Couns; 2004 Oct; 55(1):55-61. PubMed ID: 15476990
[TBL] [Abstract][Full Text] [Related]
6. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
7. [Intracavernous auto-injection therapy with papaverine phentolamine via an auto-injection pen for patients with an erectile dysfunction: similar results achieved in family practice and urology].
de Boer BJ; Lycklama a Nijeholt AA; Kleinjans HA
Ned Tijdschr Geneeskd; 2001 Apr; 145(16):783-7. PubMed ID: 11346917
[TBL] [Abstract][Full Text] [Related]
8. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.
Bong GW; Clarke HS; Hancock WC; Keane TE
Urology; 2008 Jun; 71(6):1177-80. PubMed ID: 18279929
[TBL] [Abstract][Full Text] [Related]
9. Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer.
Ulloa EW; Salup R; Patterson SG; Jacobsen PB
Psychooncology; 2009 Jun; 18(6):598-605. PubMed ID: 18942660
[TBL] [Abstract][Full Text] [Related]
10. The patient's choice of androgen-deprivation therapy in locally advanced prostate cancer: bicalutamide, a gonadotrophin-releasing hormone analogue or orchidectomy.
Nyman CR; Andersen JT; Lodding P; Sandin T; Varenhorst E
BJU Int; 2005 Nov; 96(7):1014-8. PubMed ID: 16225519
[TBL] [Abstract][Full Text] [Related]
11. "When patients have cancer, they stop seeing me"--the role of the general practitioner in early follow-up of patients with cancer--a qualitative study.
Anvik T; Holtedahl KA; Mikalsen H
BMC Fam Pract; 2006 Mar; 7():19. PubMed ID: 16549036
[TBL] [Abstract][Full Text] [Related]
12. Men's perspectives on the impact of prostate cancer: implications for oncology nurses.
Fitch MI; Gray R; Franssen E; Johnson B
Oncol Nurs Forum; 2000 Sep; 27(8):1255-63. PubMed ID: 11013906
[TBL] [Abstract][Full Text] [Related]
13. Coping and health-related quality of life in men with prostate cancer randomly assigned to hormonal medication or close monitoring.
Green HJ; Pakenham KI; Headley BC; Gardiner RA
Psychooncology; 2002; 11(5):401-14. PubMed ID: 12228873
[TBL] [Abstract][Full Text] [Related]
14. Working patterns and perceived contribution of prostate cancer clinical nurse specialists: a mixed method investigation.
Ream E; Wilson-Barnett J; Faithfull S; Fincham L; Khoo V; Richardson A
Int J Nurs Stud; 2009 Oct; 46(10):1345-54. PubMed ID: 19358991
[TBL] [Abstract][Full Text] [Related]
15. Epididymal sparing bilateral simple orchiectomy with epididymoplasty: preservation of esthetics and body image.
Issa MM; Lendvay TS; Bouet R; Young MR; Petros JA; Marshall FF
J Urol; 2005 Sep; 174(3):893-7. PubMed ID: 16093982
[TBL] [Abstract][Full Text] [Related]
16. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer.
Joly F; Alibhai SM; Galica J; Park A; Yi QL; Wagner L; Tannock IF
J Urol; 2006 Dec; 176(6 Pt 1):2443-7. PubMed ID: 17085125
[TBL] [Abstract][Full Text] [Related]
17. Attitudes of prostate cancer patients towards the diagnosis and treatment of their disease: findings from a multinational survey.
Hardy C; Penn S; Morris T
Curr Med Res Opin; 2007 Sep; 23(9):2107-16. PubMed ID: 17651536
[TBL] [Abstract][Full Text] [Related]
18. [Circumstances of prescription of hormone therapy for patients with prostate cancer].
de la Taille A
Prog Urol; 2009 May; 19(5):313-20. PubMed ID: 19393536
[TBL] [Abstract][Full Text] [Related]
19. Medical information delivered to patients: discrepancies concerning roles as perceived by physicians and nurses set against patient satisfaction.
Moret L; Rochedreux A; Chevalier S; Lombrail P; Gasquet I
Patient Educ Couns; 2008 Jan; 70(1):94-101. PubMed ID: 17988822
[TBL] [Abstract][Full Text] [Related]
20. [Recent advance in luteinizing hormone-releasing hormone analogue therapy in management of prostate cancer].
Kawai K; Akaza H
Nihon Rinsho; 1998 Aug; 56(8):2108-13. PubMed ID: 9750517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
